Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Jan-Mar;16(1):14-8.
doi: 10.4103/1319-3767.58762.

Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori

Affiliations
Randomized Controlled Trial

Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori

Salman R Hasan et al. Saudi J Gastroenterol. 2010 Jan-Mar.

Abstract

Background/aim: Resistance to metronidazole is one of the most common reasons for Helicobacter pylori treatment failure with the classic triple therapy. The clarithromycin-based regimen is not cost-effective for use in developing countries. Though furazolidone is a great substitute it has many side effects. Decreasing the duration of treatment with furazolidone to 1 week may help decrease the drug's side effects.

Aim: To study the efficacy and side effects of furazolidone when given for 1 week in combination with bismuth subcitrate, amoxicillin, and omeprazole.

Materials and methods: One hundred and seventy-seven patients with duodenal ulcer were randomly divided into two groups. Group I received omeprazole 2 Chi 20 mg + amoxicillin 2 Chi 1 g + bismuth subcitrate 4 Chi 120 mg for 2 weeks, with furazolidone 2 Chi 200 mg in the first week only. Group II received the same regimen, except that 1 week of furazolidone was followed by 1 week of metronidazole in the second week. Control endoscopy was performed after 6 weeks. Three biopsies from the antrum and three from the corpus were taken for urease testing and histology. Eradication was concluded if all tests were negative for H pylori.

Results: One hundred and fifty-seven patients completed the study. Two subjects from group I and three from group II did not tolerate the regimen and were excluded from the analysis. No serious complication was detected in any patient. The eradication rates by per-protocol (PP) analysis and intention-to-treat (ITT) analysis were 89% and 79.3% in group I and 86.6% and 74.4% in group II, respectively.

Conclusion: One week of furazolidone in combination with 2 weeks of amoxicillin, omeprazole, and bismuth subcitrate is a safe and cost-effective regimen for the eradication of H pylori. Adding metronidazole to the above regimen does not increase the eradication rate.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Comment in

  • Considerable use of furazolidone in Iran.
    Abadi AT, Taghvaei T, Vaira D. Abadi AT, et al. Saudi J Gastroenterol. 2010 Oct-Dec;16(4):308-9. doi: 10.4103/1319-3767.70631. Saudi J Gastroenterol. 2010. PMID: 20871207 Free PMC article. No abstract available.

Similar articles

Cited by

References

    1. Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther. 1995;9:59–69. - PubMed
    1. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease.NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA. 1994;6(272):65–9. - PubMed
    1. Abu-Mahfouz MZ, Prasad VM, Santogade P, Cutler AF. Helicobacter pylori recurrence after successful eradication: 5-year follow-up in the United States. Am J Gastroenterol. 1997;92:2025–8. - PubMed
    1. Tytgat GN. Review article: Treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther. 1994;8:359–68. - PubMed
    1. De Boer WA, Tytgat GN. Regular review: Treatment of Helicobacter pylori infection. BMJ. 2000;320:31–4. - PMC - PubMed

Publication types

MeSH terms